Latest News and Press Releases

Protalix to Use Funds to Aggressively Push Its Clinical Pipeline Forward and Execute Its New Strategy of Developing Clinically Superior Biologics Protalix Receives All Rights to ELELYSO in...

CARMIEL, Israel, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today pre-clinical data for PRX-106 in Non-alcoholic Steatohepatits (NASH), a...

Positive efficacy data across all disease parameters Positive safety data with low level of antibody formation End of Phase II meeting with FDA scheduled before year end CARMIEL, Israel, Sept....

CARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the second quarter of 2015. "We recently reported...

CARMIEL, Israel, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive clinical study results from the Company's Phase I trial of PRX-106,...

CARMIEL, Israel, June 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that pre-clinical data for AIR DNaseTM (PRX-110) for the treatment of Cystic...

CARMIEL, Israel, May 14, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive Officer, will...

- Losses narrowed by 19% - Interim data and full results for PRX-102 expected in the Second Half of 2015 CARMIEL, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE...

CARMIEL, Israel, March 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the year ended December 31, 2014 and provided an...

New Positive Clinical Data on Cardiac and Kidney Functions Detailed Positive Clinical Data on All Disease Parameters CARMIEL, Israel, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,...